These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39343971)

  • 1. HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma.
    Geng P; Ye F; Dou P; Hu C; He J; Zhao J; Li Q; Bao M; Li X; Liu X; Xu G
    J Exp Clin Cancer Res; 2024 Sep; 43(1):269. PubMed ID: 39343971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma.
    Zhang D; Tian X; Wang Y; Liu F; Zhang J; Wang H; Zhang N; Yan T; Lin C; Shi Z; Liu R; Jiang S
    Phytomedicine; 2024 Jul; 129():155690. PubMed ID: 38761523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
    Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma.
    Chen Z; Hu Z; Sui Q; Huang Y; Zhao M; Li M; Liang J; Lu T; Zhan C; Lin Z; Sun F; Wang Q; Tan L
    Int J Biol Sci; 2022; 18(2):522-535. PubMed ID: 35002507
    [No Abstract]   [Full Text] [Related]  

  • 5. METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression.
    Peng W; Fu J; Zhou L; Duan H
    Cancer Med; 2024 Jul; 13(13):e7420. PubMed ID: 38967523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.
    Li N; Zuo R; He Y; Gong W; Wang Y; Chen L; Luo Y; Zhang C; Liu Z; Chen P; Guo H
    Cell Death Dis; 2024 Aug; 15(8):555. PubMed ID: 39090096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HIF-1α/PKM2 Feedback Loop in Relation to EGFR Mutational Status in Lung Adenocarcinoma.
    Wang Y; Lian H; Li J; Zhao M; Hao Z; Zheng X; Zhao L; Cui J
    J Invest Surg; 2024 Dec; 37(1):2301081. PubMed ID: 38224012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
    Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma.
    Zhou Z; Li Y; Chen S; Xie Z; Du Y; Liu Y; Shi Y; Lin X; Zeng X; Zhao H; Chen G
    Cell Commun Signal; 2024 Jun; 22(1):303. PubMed ID: 38831321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis.
    Ding D; Shang W; Shi K; Ying J; Wang L; Chen Z; Zhang C
    BMC Cancer; 2024 Oct; 24(1):1270. PubMed ID: 39394098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
    Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
    Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment.
    Fu R; Du W; Ding Z; Wang Y; Li Y; Zhu J; Zeng Y; Zheng Y; Liu Z; Huang JA
    Cell Death Dis; 2021 Apr; 12(4):394. PubMed ID: 33850110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
    Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
    Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of lncRNA LOC105376794 promotes migration, invasion, and Gefitinib resistance of lung adenocarcinoma cells with EGFR 19Del mutation by ATF4/CHOP axis and ERK phosphorylation.
    Liu W; Duan Z; Wu Y; Ma R
    Neoplasma; 2024 Jun; 71(3):219-230. PubMed ID: 38958710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m
    Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z
    Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.